QuidelOrtho (NASDAQ:QDEL) Releases Earnings Results

QuidelOrtho (NASDAQ:QDEL) announced its earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18, FiscalAI reports. The company had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. QuidelOrtho’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.12 earnings per share. QuidelOrtho updated its FY 2026 guidance to 0.650-0.900 EPS.

Here are the key takeaways from QuidelOrtho’s conference call:

• Underlying business remained resilient: Q2 revenue grew 6% excluding China, with strength across labs, immunohematology, TRIAGE, and major regions outside China.
• Adjusted EBITDA rose 21% to $129 million, while EBITDA margin expanded 310 basis points to 20%, reflecting productivity improvements and disciplined expense management.
• China revenue declined 23% amid uncertainty over proposed IVD pricing guidelines, and management expects the resulting demand pressure to persist through the remainder of 2026.
• The company lowered 2026 guidance to revenue of $2.52 billion–$2.60 billion, adjusted EBITDA of $540 million–$560 million, and adjusted EPS of $0.65–$0.90, while withdrawing free cash flow guidance because of market and working-capital uncertainty.
• Management said the NULEXA point-of-care molecular platform remains on track for commercialization, with encouraging early customer engagement and expected momentum ahead of the 2027–2028 respiratory season.

QuidelOrtho Stock Down 6.7%

QuidelOrtho stock opened at $16.32 on Friday. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -0.92 and a beta of 0.68. The company’s 50 day simple moving average is $15.77 and its 200 day simple moving average is $17.59. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. QuidelOrtho has a fifty-two week low of $9.92 and a fifty-two week high of $35.58.

Institutional Investors Weigh In On QuidelOrtho

Hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System lifted its holdings in QuidelOrtho by 1.2% during the second quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock worth $1,792,000 after buying an additional 725 shares during the period. Global Retirement Partners LLC raised its holdings in shares of QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after buying an additional 886 shares during the last quarter. JPMorgan Chase & Co. lifted its position in QuidelOrtho by 0.7% during the 4th quarter. JPMorgan Chase & Co. now owns 126,404 shares of the company’s stock worth $3,610,000 after acquiring an additional 903 shares during the period. Larson Financial Group LLC boosted its position in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after buying an additional 1,015 shares during the last quarter. Finally, Comerica Bank boosted its holdings in shares of QuidelOrtho by 1.8% in the 3rd quarter. Comerica Bank now owns 77,921 shares of the company’s stock valued at $2,295,000 after acquiring an additional 1,349 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported second-quarter adjusted earnings of $0.13 per share, well above the $0.04–$0.05 loss analysts expected and ahead of $0.12 per share a year earlier. Revenue reached $631 million, exceeding the approximately $619 million consensus estimate. QuidelOrtho Q2 earnings and revenue estimates
• Positive Sentiment: Revenue grew 3% year over year, or 2% in constant currency, led by the Labs and Point-of-Care businesses. Excluding China, revenue growth was stronger at 6% on both a reported and constant-currency basis, suggesting underlying demand remains relatively healthy. QuidelOrtho Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Options-market activity showed elevated implied volatility ahead of the earnings release, indicating that investors anticipated a potentially significant post-results move. Implied volatility for QuidelOrtho options
• Negative Sentiment: QuidelOrtho lowered its fiscal 2026 outlook to $0.65–$0.90 in EPS, versus analyst expectations near $1.85, and projected revenue of $2.5–$2.6 billion, below the roughly $2.7 billion consensus. The substantial guidance gap raises concerns about slower growth or profitability pressure during the remainder of the year. QuidelOrtho full-year 2026 guidance
• Negative Sentiment: The company continues to report a deeply negative net margin, reinforcing investor concerns that the earnings beat may not represent a durable improvement in overall profitability.

Wall Street Analysts Forecast Growth

QDEL has been the topic of several research reports. JPMorgan Chase & Co. upped their price objective on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday, June 28th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. UBS Group restated a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Monday, June 15th. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $13.62.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.